Arax Advisory Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $48.9K | Buy |
150
+65
| +76% | +$21.2K | ﹤0.01% | 1244 |
|
|
2025
Q1 | $23K | Sell |
85
-396
| -82% | -$107K | ﹤0.01% | 1245 |
|
|
2024
Q4 | $113K | Sell |
481
-4
| -0.8% | -$941 | 0.01% | 646 |
|
|
2024
Q3 | $133K | Buy |
485
+4
| +0.8% | +$1.1K | 0.01% | 436 |
|
|
2024
Q2 | $117K | Buy |
+481
| New | +$117K | 0.01% | 445 |
|
|
2024
Q1 | – | Sell |
-21
| Closed | -$4.02K | – | 1315 |
|
|
2023
Q4 | $4.02K | Buy |
21
+13
| +163% | +$2.49K | ﹤0.01% | 923 |
|
|
2023
Q3 | $1.42K | Buy |
8
+5
| +167% | +$886 | ﹤0.01% | 1073 |
|
|
2023
Q2 | $570 | Sell |
3
-5
| -63% | -$950 | ﹤0.01% | 1191 |
|
|
2023
Q1 | $1.6K | Hold |
8
| – | – | ﹤0.01% | 1023 |
|
|
2022
Q4 | $1.9K | Hold |
8
| – | – | ﹤0.01% | 954 |
|
|
2022
Q3 | $2K | Buy |
+8
| New | +$2K | ﹤0.01% | 934 |
|